Sensulin, LLC

Sensulin, LLC is a preclinical biopharmaceutical company dedicated to developing glucose-responsive insulin, targeting enhanced diabetes management for individuals with type 1 and type 2 diabetes. Founded in 2011 and headquartered in Oklahoma City, US, Sensulin, LLC is committed to innovating diabetes care through its glucose-responsive insulin. The company has engaged in six key funding deals, with its latest investment round occurring in October 2021, where it raised USD 2. 70 mn in a Series A round.

The founder, Chris Rhodes, brings prior entrepreneurial experience to the company, which aims to advance diabetes management solutions globally. Sensulin focuses on developing a groundbreaking glucose-responsive insulin, which seeks to reduce the risk of hypoglycemia and mitigate long-term diabetic complications such as eye and kidney diseases. By potentially replacing separate basal and mealtime insulin, their product aims to improve the quality of life for diabetes patients. The target audience includes diabetes patients, healthcare providers, and hospitals in the US and selected international markets.

Sensulin's revenue strategy revolves around partnerships and direct engagements with healthcare providers and patients. Through a direct-to-consumer approach, it anticipates providing its glucose-responsive insulin primarily to diabetes patients, potentially involving subscription services and supply contracts with healthcare institutions to ensure efficient access to their offerings. With the recent funding raised in October 2021, Sensulin plans to accelerate the development of its glucose-responsive insulin and expand into new markets. The company is focusing on broadening its reach within the US and targeting select international markets, aiming for a more extensive rollout of its innovative solutions by leveraging the new venture funding to support product development and market penetration efforts.